Facing a delay of clinical trials for its lead therapy, Neurogen slashed 45 more jobs and announced plans to focus its development programs. The developer also raised $30.6 million in a private placement with institutional investors. That money will be used to advance research for the company's four clinical programs in insomnia, anxiety, restless legs syndrome, and Parkinson's disease. Release